Name: Latest research reports of Dr. Reddy's Laboratories Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Dr. Reddy's Laboratories Ltd.
Rating: 5
Author: Axis Direct

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	16 Oct 2025	Dr. Reddy's Labs	Consensus Share Price Target	1232.40	1292.67	-	4.89	hold	pdf Detailed Estimates
	26 Dec 2022	Dr. Reddy's Labs	Axis Direct Target	1232.40	4750.00	4248.60 (-70.99%)	Target met	Buy	pdf post cache	Broker Report Pick of the Week:26 DEC 2022 Axis Direct We recommend a BUY rating on the stock with a target price of Rs 4,750/share, implying an upside of 10% from the CMP. pdf Copy Link Share on Share on Share on Share on Alert
	01 Nov 2022	Dr. Reddy's Labs	Axis Direct Target	1232.40	5000.00	4535.30 (-72.83%)	Target met	Buy	pdf post cache	Broker Report Result Update:Dr Reddys Labs Axis Direct We recommend a BUY rating on the stock with a TP of Rs 5,000/share. pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2022	Dr. Reddy's Labs	Prabhudas Lilladhar Target	1232.40	4900.00	4535.30 (-72.83%)	Target met	Buy	pdf post cache	Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2022	Dr. Reddy's Labs	SMC online	1232.40		4555.65 (-72.95%)	Pre-Bonus/ Split	Results Update	pdf post cache	Broker Report Dr Reddys Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2022	Dr. Reddy's Labs	ICICI Securities Limited Target	1232.40	5134.00	4459.95 (-72.37%)	Target met	Buy	pdf post cache	Broker Report Revlimid springs surprise; outlook intact ICICI Securities Limited Dr. Reddy’s Laboratories’ (DRL) Q2FY23 reported performance exceeded our and consensus estimates, largely driven by strong sales of Revlimid and recovery of US base and Russia sales. pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2022	Dr. Reddy's Labs	BOB Capital Markets Ltd.	1232.40		4433.70 (-72.20%)	Pre-Bonus/ Split	Hold	pdf post cache	Broker Report Dr Reddy's Labs (HOLD): US launch of gRevlimid buoys quarter BOB Capital Markets Ltd. Q2 revenue up 9% YoY on sales of gRevlimid in the US; gross margin expansion aids EBITDA growth of 42% YoY pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2022	Dr. Reddy's Labs	ICICI Direct Target	1232.40	5215.00	4459.95 (-72.37%)	Target met	Buy	pdf post cache	Broker Report Dr Reddy's Laboratories ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2022	Dr. Reddy's Labs	Motilal Oswal Target	1232.40	5180.00	4433.70 (-72.20%)	Target met	Buy	pdf post cache	Broker Report Russia recovers, while PSAI still a drag on earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	01 Aug 2022	Dr. Reddy's Labs	SMC online	1232.40		4096.30 (-69.91%)	Pre-Bonus/ Split	Results Update	pdf post cache	Broker Report Dr. Reddy`s Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2022	Dr. Reddy's Labs	Prabhudas Lilladhar Target	1232.40	4750.00	4110.45 (-70.02%)	Target met	Buy	pdf post cache	Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
more loading

Dr. Reddy's Laboratories Ltd. share price target

Dr. Reddy's Laboratories Ltd. has an average share price target of 1278.56. The consensus estimate represents an upside of 3.75% from the last price of 1232.40. View 18 reports from 9 analysts offering long-term price targets for Dr. Reddy's Laboratories Ltd..

Pick of the Week:26 DEC 2022

Result Update:Dr Reddys Labs

DR REDDY'S LABS

Dr Reddys Laboratories

Revlimid springs surprise; outlook intact

Dr Reddy's Labs (HOLD): US launch of gRevlimid buoys quarter

Dr Reddy's Laboratories

Russia recovers, while PSAI still a drag on earnings

Dr. Reddy`s Laboratories

DR REDDY'S LABS

Advisor Screeners